clinical trial · NCT07315750
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
RemeGen Co., Ltd.·phase3·recruiting·n = 555
Gastric CarcinomaDisitamab VedotinTislelizumabCAPOX (oxaliplatin/capecitabine)TrastuzumabPembrolizumab
brief summary
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with or without Pembrolizumab as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma with HER2-high Expression.
started
Jan 1, 2026
primary completion
Jun 30, 2029
completion
Dec 31, 2030
last updated
Jan 21, 2026
official title
A Randomized Controlled Phase III Study to Evaluate the Combination of Disitamab Vedotin, Trastuzumab, and Tislelizumab Versus Chemotherapy (CAPOX) Combined With Trastuzumab With or Without Pembrolizumab as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma With HER2-high Expression
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol